Bristol-Myers Squibb has exited Taris, which is developing a drug delivery system for bladder diseases, in a purchase by Johnson & Johnson.
Medical product group Johnson & Johnson acquired US-based drug delivery technology developer Taris Biomedical on Friday for an undisclosed amount, allowing pharmaceutical company Bristol-Myers Squibb to exit.
Taris has created a silicon-based drug delivery system intended for use with therapeutics for bladder disease, including related cancers. The TAR-200 device enables medication to be continuously released into the bladder, and the technology stems from research at MIT.
Peter Lebowitz, therapeutic area head of oncology for Johnson & Johnson subsidiary Janssen Research…
